Adalimumab biosimilar (Shanghai Henlius Biotech)

阿达木单抗生物类似药（复宏汉霖）

Report date: 2024/05/24 15:10:51

Base Information

Drug NameAdalimumab biosimilar (Shanghai Henlius Biotech)
Drug Alias Name阿达木单抗生物仿制药（复宏汉霖）Recombinant anti - TNFα antibody (Shanghai Henlius Biotech)重组抗TNFα全人单抗（复宏汉霖）汉达远HLX-03
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisImmune System DiseasesPsoriasis +[11] 
Global Approved IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Approved Indications in ChinaPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryMainland China
Original Approved Date2020/12/02
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesAl Tiryaq Al-Khalawi Medical CompanyGetz PharmaShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsPsoriasisUveitis, IntermediateUveitis, Posterior +[9] 
Inactive IndicationsPlaque psoriasisImmune System Diseases

Other Information

ATC CodeL04AB04
Related LinksN/A